

Supplementary Materials

Article

Evodiamine mitigates cellular growth and promotes apoptosis by targeting the c-Met pathway in prostate cancer cells

Sun Tae Hwang ¹, Jae-Young Um ¹, Arunachalam Chinnathambi ², Sulaiman Ali Alharbi ², Acharan S. Narula ³, Ojas A. Namjoshi ⁴, Bruce E. Blough ⁴ and Kwang Seok Ahn ^{1,*}

¹ Department of Science in Korean Medicine, Kyung Hee University, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; suntaeh12@gmail.com (S.T.H.), jyum@khu.ac.kr (J.-Y.U.)

² Department of Botany and Microbiology, College of Science, King Saud University, Riyadh -11451, Kingdom of Saudi Arabia; carunachalam@ksu.edu.sa (A.C.), sharbi@ksu.edu.sa (S.A.A.)

³ Narula Research, Chapel Hill, NC 27516, USA, anarula1@nc.rr.com

⁴ Center for Drug Discovery, RTI International, Research Triangle Park, Durham, NC, USA 27616, onamjoshi@rti.org (O.A.N.), beb@rti.org (B.E.B.)

* Correspondence: ksahn@khu.ac.kr Phone: 82-2-961-2316




Figure S1. Effect of EVO in others signaling cascades such as MAPKs, PI3K/Akt, and NF- κ B. (A–B) Both cells were seeded in six-well plates and incubated overnight in serum-free conditions. Then, they were pre-treated with EVO for 4 h and treated with HGF for 15 min in serum-free conditions. Whole cell extracts were prepared and immunoblotted with indicated antibodies. (C) Both cells were prepared same condition as previous. Nuclear extracts and cytoplasmic extracts were prepared and immunoblotted with indicated antibodies.